This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Hope so i bought in to this a bit late..

Down 6p now, a great opportunity for those who missed out earlier to jump on board.

cheers GF.

Ive just added on the pull back, these could turn out to be derd cheap and we know that 6 or more products are going into clinical trials this year.

From results December...............

In addition to the Oncosense clinical trials, we continue to make progress with
our anti-viral business, Viratis where I am pleased to report that the European
patent was formally granted. Genvax, our DNA vaccine business, is also
progressing. Some of the DNA vaccines are already in clinical trials involving
cancer patients and other cancer vaccines are due to enter clinical trials
shortly. Overall we expect to have some six or more products in clinical trials
in 2005, with the results of some of these trials being available in the first
half of the year. Our pharmaceutical portfolio is therefore most promising

Those who have sold this morning must be stark raving mad.

cheers GF.

WOW, just look at those buys coming in and the price as come back in aswell. Come on MMG we want you in the blue before the days out.

cheers GF.

GF ,I got in late on this one and nearly sold out today, thanks for the reasurance Jb

Hi Jimmy, please remember its a very sensitive one this with a very high beta.

6 or more product annoucements the first later this month shouls assure holders and entice new buyers in.

cheers GF.

In on this one at 103p. That rally after the sell off convinced me this one's stil got a way to go.

More from Mike..Its free....

http://www.michaelwalters.com/stories/news.phtml?num=2416

From Mike Walters,..............................


A Safer Bet
28/1/2005 (119264)

A Safer Bet

Despite the increasing incidence of outright manipulation and abuse, there is no point in arguing with the market. The share price is the price, whether you think it right, wrong, or simply fiddled by cheats and conmen. No-one is going to pay you what you think a share is worth just on the evidence of your say-so.

That leads us all into frustration from time to time, and can make us look silly. Every so often, though, it means we have spotted an opportunity. The price might be right at the time of asking but given a little longer, the market might come around to your way of thinking.

Such thoughts have come to mind at Medical Marketing International (MMG) regularly in recent months. This baby bio incubator really does appear to have some outstanding drugs in the early stages of development. As they move down the line towards market (still well in the distance), the increasing notional value which is being added simply does not appear to be reflected in the share price.

That made it unusually good news today (Friday) when the price jumped to 83.5p in early trading on an announcement that the companys ruthenium cancer therapy had passed independently verified safety tests. It then slipped back, but held through the day to close at 81p, a gain of 9p, with over 1.2million shares traded, huge volume for such a stock.

We have been here before. Back in the tech boom, we went soaring way over 100p. Earlier this year, we topped out at around these levels. In the boom days, the business was nowhere near as promising as now and though a price of more than 80p looked reasonable last year, it failed to hold.

All of this is a prolonged exercise in warning that MMI shares are volatile, and you should not rely upon further short term gains. But, by golly, they do look worth buying at these levels, and could go very significantly higher over the next 12 months.

Go back to the several stories I have filed over the past year. Read them in my archives, and check what was in my monster round-up Where We Are on January 1. That gives a thumbnail sketch of what this business is about highly promising progress in advancing ruthenium as a superior compound to platinum in the fight against cancer, plus good progress in 50% owned Genvax on a DNA vaccine.

This is not simple stuff, and it is not for the risk-averse. The majority of such drugs stumble somewhere in the development process, and disappear. If they win through, however, some could be worth a fortune. A real goodie could be worth 200m to 1bn to the company which comes up with it.

Hold tight. It would be wrong to suggest MMI has anything yet worth such figures. But the market capitalisation at 81p is around 38m, so there could be a long way to go.

Ruthenium is emerging as a remarkable opportunity. The latest announcement suggests that independent lab tests show the leading ruthenium compounds in the MMI portfolio are pretty much as safe as any cancer drug can be. Tested by specialist CXR Biosciences of Dundee, the compounds show toxicity even safer than tamoxifen in an industry standard lab model.

Mark Burton, technical manager at MMI, says CXR was chosen because it has highly regarded skills in screening new drugs for harmful effects. When combined with existing efficacy data, the results show ruthenium has great clinical potential.

David Best, chairman of MMI, says data already shows ruthenium to be potentially the most effective drug against serious cancers like lung, colon and ovarian, and the new data shows it is potentially relatively safe. If the results are confirmed in clinical trials, ruthenium may improve standard cancer treatment significantly. It could be a major commercial success in a cancer therapy market which was worth $42bn in 2004 and continues to grow in double-digit figures.

These vast figures need breaking down. At peak sales, platinum compounds were worth $5bn. Since they have come off patent, the value has fallen, but volumes have risen.

Platinum is still a valuable and important anti-cancer treatment, but it has nasty side effects, especially in damaging kidneys. Some compounds do better. Tamoxifen is the generic name for Zenecas Nolvadex, which has become the standard treatment for breast cancer since introduction in 1969. It is so widely accepted now, and considered so safe that it is given as a possible preventative measure to ladies considered at risk of breast cancer. Ruthenium appears so far to be safer than tamoxifen, and so could be used at an earlier stage of treatment than other compounds.

At this stage and please note these reservations, which are relevant to any serious assessment of progress ruthenium is highly promising. It has been tested in human cells, but not yet in humans.

It has gone almost as far as possible in the lead up to this crucial phase 11 testing. Is it now ready for that?

Dr Cliff Elcombe, a director of CXR and a former senior scientist at Zeneca, is quoted by MMI as suggesting that the safety screens his company performed indicate this new group of cancer therapies has enormous potential.

He sounded as if he was at Amsterdam airport when I caught up with him, and was happy to confirm the quotation. He suggested that there could be a few more tests before clinical trials but there shouldnt be major problems.

He said; If these were my compounds, Id be very happy at this stage.

Sounds good? Sure. But you need to keep in mind that any prudent commentator slips in those reservations.

At this stage, ruthenium is obviously doing extremely well. The data on efficacy suggests the best MMI compounds perform very much better than alternatives in six major cancer types colon, melanoma, pancreas, ovarian, oesophageal, and lung. The performance is measured against carboplatin (the original $5bn seller, now selling $1bn a year as a generic), a more powerful compound called cisplatin, and oxaliplatin, a more recent introduction.

We are not talking minor gains. In every example, ruthenium performs more than twice as well as the other compound, and in most areas the ruthenium advantage is much more significant.

The next step, clearly, is to move into clinical trials with humans. This should happen soon, and is likely to involve three compounds, one more than had earlier been expected.

Monitoring progress in the fight against cancer can be relatively simple. Is the tumour growing or not? How fast is it growing?

The evidence can be apparent in two or three weeks, though full trials obviously take longer. It is reasonable to speculate that MMI could have the results of phase 11 trials before the end of the year. It would be no surprise if sufficient data was available earlier, allowing serious negotiations with possible big pharma partners in that time span.

At that stage, we are talking about big money commitments. A big brother would licence the product for a sizeable upfront payment to MMI and the promise of royalties on sales, possibly with milestone payments. The possible figures no guarantees, nothing certain could make MMIs market capitalisation look extremely modest.

Once again, this is speculative stuff. But ruthenium is not the only promising compound in the MMI portfolio. The company has 50% of Genvax which is in clinical trials with a DNA vaccine platform technology. These trials started in 2001, and the last patient joined early in 204. In September, I suggested full evaluation of the results could emerge by March this year.

There are other compounds, other possibilities in the MMI portfolio. Six or seven are likely to move into clinical trials this year. That is as big a pipeline as in some of the big pharma boys. No wonder some institutions have been keen to pick up shares in MMI, and were ready to step forward again in November to put up 2.2m at 70p a share.

Best has made it clear that he believes 2005 will be a very good year for MMI. He and his wife, director Margaret Mitchell, sold shares to let the Pru in last spring, but are still substantial holders, strongly committed to the company.

It would be foolish to guarantee that any of the MMI compounds will succeed in the end, though given that ruthenium has many similar characteristics which seem to make it a more effective alternative to the long-established platinum, there are strong grounds for optimism.

It would be silly, too, to guarantee that the underlying volatility in the share price is spent, and that there will be good progress from this point. Once again, though, there is ample room for hope. We can expect good news flow in the weeks and months ahead.

I have been recommending the shares since they were 66p to 69p in April, and they have behaved erratically, each rise being followed by a fall. But step by step, the argument has been getting stronger, and progress in developing exciting drugs has been good. The shares remain an outstanding speculation at 81p. Go for it.

Ends.


cheers GF.

Buys coming in.

cheers GF.

Price showing incredible resilience to profit taking.......... 214 - good post gf....... could see another 5 p/c gain today

good luck . Rob

Goldfinger dont forget MW copywrite. He will not be pleased to see his report on moneyam.

I was told it was a free report.!!!!!!!!!!!!!!!.

Anyway nice to see this one getting back to more or less evens. Remember 6 product trials or more means lots of news flow.

cheers GF.

Its just turned positive, NICE.

cheers GF.

News is due by the end of the month ..fingers crossed.. its not worth selling now when they could be worth another 30%....

News by the end of the month Mitzy great , yuve been right all along wiith your info so Ill go for that.

cheers GF.

Somethings brewing behind the scenes GF its a question of waiting for the right news to happen....any news on phase 2 will send these up another 30% in a day!.Hold tight.
"brewing".. geddit..?

Nice one Mitzy.

cheers Gf

Nice start to the day..Why the rise,?

Keep on buying.. everyone else is...